Investigating the effects of early antibiotic use in newborns with very low birth weight
The NICU Antibiotics and Outcomes (NANO) Trial
The NANO Trial is looking into whether giving antibiotics right after birth helps or harms extremely low birthweight babies, so doctors can make better decisions about their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10677891 on NIH RePORTER |
What this research studies
The NANO Trial focuses on the practice of giving intravenous antibiotics to extremely low birthweight (ELBW) infants right after birth. These infants often receive antibiotics for a few days while doctors wait for test results to check for infections. The research aims to determine if this early antibiotic treatment actually improves health outcomes or if it could potentially cause harm, especially considering the impact of antibiotics on the developing microbiome. By analyzing data on health outcomes, the study seeks to clarify the benefits and risks of this common practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are newborns classified as extremely low birthweight (ELBW) infants who are at risk for early onset sepsis.
Not a fit: Patients who are not newborns or those who do not fall into the extremely low birthweight category may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment protocols for newborns, potentially reducing unnecessary antibiotic exposure and its associated risks.
How similar studies have performed: While the approach of studying antibiotic effects in newborns is not widely tested, there is emerging evidence suggesting that antibiotic exposure can have significant long-term effects on health outcomes.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Morowitz, Michael — University of Pittsburgh at Pittsburgh
- Study coordinator: Morowitz, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.